Tradeoffs Generic Drugs Head to the Supreme Court
Mar 26, 2026
Leslie Walker, senior health policy reporter who covers drug pricing, breaks down Hikma v. Amarin and what it could mean for generic competition. She explains skinny labeling, the companies and drug at issue, and how court rulings might raise costs or chill generics. Short takes on litigation costs, business incentives, and possible Supreme Court outcomes.
AI Snips
Chapters
Transcript
Episode notes
How Skinny Labels Let Generics Enter Market Early
- Skinny labeling lets generics enter market for unpatented uses while avoiding costly patent fights.
- Hikma used a skinny label for Vascepa's narrow indication after one patent expired, prompting Amarin's induced-infringement lawsuit.
When Marketing Can Trigger Patent Claims
- Induced infringement claims hinge on whether a generic's labeling or communications cause doctors to prescribe it for still-patented uses.
- Amarin points to Hikma's vague label and a press release citing $1 billion total sales as evidence of 'nudging.'
Market Substitution Makes Skinny Labels Potent
- Once a generic is marketed, pharmacists and doctors can legally substitute it broadly, undermining brand sales for other patented indications.
- That practical substitution is why brands fear skinny-labeled generics even if patents remain for other uses.